Payment overview · 2025
General Payments
$324.08
15 reported records · 10 companies
Healthcare provider profile · identity verified
Oganes Paronian, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH HOLLYWOOD, CA · NPI 1528048899
Verified facts
What the public records show
CMS Open Payments records show Oganes Paronian, MD received $324.08 in general payments during 2025 across 15 reported records.
SHIELD THERAPEUTICS INC accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Linzess by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $110.63 | 34.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.30 | 11.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.31 | 10.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.90 | 8.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $26.28 | 8.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.78 | 6.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.87 | 5.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.64 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.51 | 4.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.86 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $324.08 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $110.63 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.31 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.31 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.90 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $26.28 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
215 | 28 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
275 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
254 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1097 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 967 | 146 |
| Omeprazole | Omeprazole | 840 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 688 | 95 |
| Metformin Hcl | Metformin Hcl | 677 | 104 |
| Lisinopril | Lisinopril | 620 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 511 | 68 |
| Gabapentin | Gabapentin | 497 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 485 | 78 |
| Clonidine Hcl | Clonidine Hcl | 465 | 69 |
| Losartan Potassium | Losartan Potassium | 423 | 61 |
| Ibuprofen | Ibuprofen | 387 | 59 |
| Carvedilol | Carvedilol | 356 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 356 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 41 |
| Vascepa | Icosapent Ethyl | 304 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 293 | 44 |
| Furosemide | Furosemide | 285 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 282 | 56 |
| Jardiance | Empagliflozin | 275 | 41 |
| Meloxicam | Meloxicam | 263 | 37 |
| Tramadol Hcl | Tramadol Hcl | 257 | 37 |
| Ozempic | Semaglutide | 254 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 225 | 29 |
| Mirtazapine | Mirtazapine | 224 | 36 |
| Naproxen | Naproxen | 221 | 33 |
| Celecoxib | Celecoxib | 219 | 30 |
| Linzess | Linaclotide | 215 | 28 |
| Finasteride | Finasteride | 207 | 32 |
| Enalapril Maleate | Enalapril Maleate | 200 | 30 |
| Simvastatin | Simvastatin | 187 | 28 |
| Benazepril Hcl | Benazepril Hcl | 184 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 178 | 24 |
| Farxiga | Dapagliflozin Propanediol | 177 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 25 |
| Chlorthalidone | Chlorthalidone | 164 | 24 |
| Icosapent Ethyl | Icosapent Ethyl | 164 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 18 |
| Lorazepam | Lorazepam | 156 | 28 |
| Ezetimibe | Ezetimibe | 155 | 23 |
| Glipizide | Glipizide | 145 | 23 |
| Temazepam | Temazepam | 145 | 30 |
| Famotidine | Famotidine | 139 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 19 |
| Clonazepam | Clonazepam | 136 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 134 | 20 |
| Alendronate Sodium | Alendronate Sodium | 128 | 14 |
| Sertraline Hcl | Sertraline Hcl | 128 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 126 | 20 |
| Meclizine Hcl | Meclizine Hcl | 126 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 125 | 21 |
| Januvia | Sitagliptin Phosphate | 125 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 14 |
| Atenolol | Atenolol | 115 | 19 |
| Propranolol Hcl | Propranolol Hcl | 114 | 16 |
| Alprazolam | Alprazolam | 113 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 109 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 105 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 102 | 16 |
| Potassium Chloride | Potassium Chloride | 102 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 16 |
| Memantine Hcl | Memantine Hcl | 96 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 94 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 94 | 15 |
| Fenofibrate | Fenofibrate | 93 | 14 |
| Glimepiride | Glimepiride | 92 | 13 |
| Eliquis | Apixaban | 90 | 14 |
| Creon | Lipase/Protease/Amylase | 87 | 15 |
| Ketoconazole | Ketoconazole | 87 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 86 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 18 |
| Belsomra | Suvorexant | 82 | 16 |
| Donepezil Hcl | Donepezil Hcl | 78 | 11 |
| Montelukast Sodium | Montelukast Sodium | 76 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | suppressed |
| Nifedipine Er | Nifedipine | 74 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 72 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 70 | 15 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 70 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 70 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 68 | 25 |
| Lansoprazole | Lansoprazole | 67 | suppressed |
| Repatha Sureclick | Evolocumab | 67 | 11 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 66 | 12 |
| Allopurinol | Allopurinol | 65 | 11 |
| Clonidine | Clonidine | 64 | suppressed |
| Procto-Med Hc | Hydrocortisone | 64 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 62 | 17 |
| Valsartan | Valsartan | 62 | 14 |
| Novolog Flexpen | Insulin Aspart | 61 | 13 |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Digoxin | Digoxin | 59 | suppressed |
| Trulicity | Dulaglutide | 59 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | suppressed |
| Lovastatin | Lovastatin | 57 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 54 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 19 |
| Azelastine Hcl | Azelastine Hcl | 51 | 12 |
| Colchicine | Colchicine | 49 | suppressed |
| Restasis | Cyclosporine | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 14 |
| Fluocinonide | Fluocinonide | 48 | 13 |
| Irbesartan | Irbesartan | 48 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 48 | 13 |
| Clotrimazole | Clotrimazole | 46 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | suppressed |
| Lubiprostone | Lubiprostone | 45 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 45 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 44 | suppressed |
| Rybelsus | Semaglutide | 43 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 42 | suppressed |
| Gemfibrozil | Gemfibrozil | 42 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 38 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 14 |
| Bumetanide | Bumetanide | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Dutasteride | Dutasteride | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Ibu | Ibuprofen | 28 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Captopril | Captopril | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 25 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | suppressed |
| Dayvigo | Lemborexant | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Mitigare | Colchicine | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Verquvo | Vericiguat | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Lofena | Diclofenac Potassium | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 11 | suppressed |
| Easy Touch Safety Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $324.08 · 15 records | SHIELD THERAPEUTICS INC | ACCRUFER, AREXVY, BEXSERO, BEYFORTUS, DUPIXENT, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Kerendia, OTEZLA, QULIPTA, REPATHA, SHINGRIX, Saxenda, UBRELVY, Wegovy, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error